FDA Recalls Finder

FDA Updates Earlier Guidance on Respiratory Treatment Spiriva HandiHaler
14 January 2010, 1:38 pm

The U.S. Food and Drug Administration today announced that data from a recent review of the Spiriva HandiHaler, a long-acting respiratory treatment for chronic obstructive pulmonary disease (COPD), do not support an increased risk of stroke, heart attack, or death in patients using the medicine.

Source: Food and Drug Administration--Press Releases